4215 Sorrento Valley Boulevard92121 San Diego , California
Ambit Biosciences Incorporated
Registration country:United States
A biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer.
Ambit Biosciences has multiple drug candidates in clinical development, including Quizartinib a selective class III receptor tyrosine kinase inhibitor for treatment of acute myeloid leukaemia, currently in Phase II clinical trials.